Azora Therapeutics AZR 深 沪
等待开盘 11-13 09:30:00 美东时间
3.74
+0.230
+6.55%
华盛通- 最 高4.035
- 今 开3.59
- 成交量 5.08万股
- 最 低 3.4277
- 昨 收 3.51
- 总市值 0
- 52周最高 8.245
- 市盈率 静 --
- 换手率 Infinity.00%
- 52周最低 1.31
- 委 比 -99.49%
- 总股本 0
- 历史最高 5900.00
- 量 比 1.14
- 振 幅 17.30%
- 历史最低 3.3075
- 每 手 1
- 风险率 1.96%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Azora Therapeutics Reports 2026 Third Quarter Financial Results and Provides Business Update
Azora Therapeutics, a biopharmaceutical company, began trading on Nasdaq as "AZR" and appointed a new executive team and Board of Directors. The company is advancing its AT177 program, targeting an IND submission and Phase 1a trial in the first half of 2027. AT177 is an oral, colon-targeted AhR agonist for ulcerative colitis. The company reported a net loss of $64.6 million for Q3 2026 and had $22 million in cash as of September 30, 2026.
11-12 21:05
美股大行评级 | 潜在涨幅2250.23%！艾伯维获大摩等多家大行上调目标价，最高340美元
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从50美元升至51美元；HC Wainwright & Co.：上调伊诺维奥制药评级至"买入"，目标价5美元
11-03 18:20
Jones Trading Initiates Coverage On Azora Therapeutics with Buy Rating, Announces Price Target of $14
Jones Trading analyst Debanjana Chatterjee initiates coverage on Azora Therapeutics (NASDAQ:AZR) with a Buy rating and announces Price Target of $14.
11-02 20:20
